Leukemia clinical trials

Explore recruiting leukemia clinical trials.

Recruiting leukemia studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, prospective, multi-center intervention trial in patients with acute myeloid leukemia secondary to myeloproliferative neoplasms unfit for intensive chemotherapy investigating a treatment combination including decitabine and venetoclax. ENABLE (vENetoclax plus decitAbine treatment in Blastic phase of myeLoproliferative nEoplasms). AML2420

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

CAALL-F01: a French protocol for the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

STEP-WISE COMBINATION OF OBINUTUZUMAB, VEMURAFENIB AND COBIMETINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) PREVIOUSLY TREATED WITH PURINE ANALOGS OR UNFIT FOR CHEMOTHERAPY: A PHASE-2, SINGLE-ARMS, ITALIAN, MULTICENTER STUDY (HCL-PG04)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)

Italy, Bulgaria, Denmark, Spain, Poland, Belgium +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy

Spain, France, Italy, Germany, Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

VEN-R DASA-IPC 2022-067 Evaluation of DASATINIB monotherapy in acute myeloid leukemia patients refractory to VENETOCLAX-AZACITIDINE

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Leukemia trials by city

Leukemia in Toronto Leukemia in Vancouver Leukemia in Montreal Leukemia in Calgary Leukemia in Edmonton Leukemia in Ottawa Leukemia in Winnipeg Leukemia in Quebec City Leukemia in Hamilton Leukemia in Kitchener Leukemia in London Leukemia in Halifax Leukemia in New York Leukemia in Los Angeles Leukemia in Chicago Leukemia in Houston

Leukemia clinical trials

Recruiting leukemia studies right now

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment

Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

Luspatercept for CIA in AML

Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

A Study of Chidamide With AZA in MRD Positive AML After Transplant

Also recruiting in Europe

CAALL-F01: a French protocol for the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents

STEP-WISE COMBINATION OF OBINUTUZUMAB, VEMURAFENIB AND COBIMETINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) PREVIOUSLY TREATED WITH PURINE ANALOGS OR UNFIT FOR CHEMOTHERAPY: A PHASE-2, SINGLE-ARMS, ITALIAN, MULTICENTER STUDY (HCL-PG04)

Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)

A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy

VEN-R DASA-IPC 2022-067 Evaluation of DASATINIB monotherapy in acute myeloid leukemia patients refractory to VENETOCLAX-AZACITIDINE

Leukemia trials by city

Other conditions